These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 24721422

  • 21. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
    Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, Swiss Clinical Quality Management Physicians.
    Arthritis Rheum; 2009 May 15; 61(5):560-8. PubMed ID: 19405000
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 15; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, Hyrich KL, BSRBR Control Centre Consortium.
    Ann Rheum Dis; 2015 Jun 15; 74(6):1087-93. PubMed ID: 24685910
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E, Bortoluzzi A, Carrara G, Zanetti A, Govoni M, Scirè CA.
    BMJ Open; 2018 Sep 11; 8(9):e021447. PubMed ID: 30206082
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P.
    Joint Bone Spine; 2012 Dec 11; 79(6):591-6. PubMed ID: 22480748
    [Abstract] [Full Text] [Related]

  • 30. Treatment patterns of anti-TNF agents in Italy: an observational study.
    Punzi L, Matucci Cerinic M, Cantini F, Bagnato G, Fiocco U, Ferri C, Bombardieri S.
    Reumatismo; 2011 Mar 11; 63(1):18-28. PubMed ID: 21509346
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
    Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS.
    Rheumatology (Oxford); 2015 Jul 11; 54(7):1226-35. PubMed ID: 25573840
    [Abstract] [Full Text] [Related]

  • 32. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.
    Titos Arcos JC, Hallal H, Robles M, Andrade RJ.
    Rev Esp Enferm Dig; 2012 May 11; 104(5):282-4. PubMed ID: 22662786
    [No Abstract] [Full Text] [Related]

  • 33. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease.
    Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L.
    Joint Bone Spine; 2007 Mar 11; 74(2):148-54. PubMed ID: 17368068
    [Abstract] [Full Text] [Related]

  • 34. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
    Ip K, Hartley L, Solanki K, White D.
    N Z Med J; 2015 May 29; 128(1415):34-40. PubMed ID: 26117510
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
    Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P.
    Cochrane Database Syst Rev; 2009 Oct 07; 2009(4):CD007848. PubMed ID: 19821440
    [Abstract] [Full Text] [Related]

  • 37. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
    Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T.
    Scand J Rheumatol; 2007 Oct 07; 36(6):411-7. PubMed ID: 18092260
    [Abstract] [Full Text] [Related]

  • 38. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
    Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M, REAL Study Group.
    Ann Rheum Dis; 2012 Nov 07; 71(11):1820-6. PubMed ID: 22504558
    [Abstract] [Full Text] [Related]

  • 39. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, Hartkamp A, van de Laar MA, van Riel PL.
    Ann Rheum Dis; 2013 Jun 07; 72(6):895-900. PubMed ID: 22887849
    [Abstract] [Full Text] [Related]

  • 40. Infection risk in patients with rheumatoid arthritis treated with etanercept or adalimumab.
    Chiang YC, Kuo LN, Yen YH, Tang CH, Chen HY.
    Comput Methods Programs Biomed; 2014 Oct 07; 116(3):319-27. PubMed ID: 25022467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.